Rekvina Lab Peer Comparison

BSE: 526075

₹53.00

₹-0.84 (-1.56%)

As on 22-Sep-2026IST

Market cap

₹59 Cr

Revenue (TTM)

₹2 Cr

P/E Ratio

--

P/B Ratio

13.4

Div. Yield

0 %

Edit

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	59	35,504	27,675	26,306	27,978
Revenue (₹ Cr)	2	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-0.34	414.00	288.22	387.35	-371.81
Net Margin (%)	-17.58	11.23	14.79	26.01	-3.93
RoE (%)	--	8.38	29.77	25.18	-3.85
Price to Earnings	--	86.81	96.02	68.11	--
Price-To-Book	13.45	7.05	20.62	15.25	3.50

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	1.93	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	1.93	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	2.27	2,792.00	1,485.56	919.25	8,195.15
EBITDA	-0.34	772.00	450.24	542.56	1,010.13
Depreciation	0.00	226.00	50.83	37.68	857.51
EBIT	-0.34	546.00	399.41	504.88	152.62
Interest	0.00	217.00	40.84	3.77	342.73
Other Income	0.00	122.00	12.78	27.45	244.31
Exceptional Items	0.00	12.00	0.00	0.00	-216.88
Profit before Tax	-0.34	463.00	371.35	528.56	-162.68
Provision for Tax	0.00	49.00	83.14	141.21	209.13
Profit after Tax	-0.34	414.00	288.22	387.35	-371.81

Liabilities (₹ Cr)

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	-1.23	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	0.00	1,712.00	202.03	42.40	5,044.14
Current Liabilities	2.42	1,622.00	835.87	230.82	4,758.28
Total Liabilities	0.03	8,100.00	1,451.43	1,549.26	15,513.53

Assets (₹ Cr)

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	0.00	5,343.00	519.60	1,026.85	10,211.52
Current Assets	1.19	2,606.00	1,681.81	881.27	7,191.66
Total Assets	0.03	8,100.00	1,451.43	1,549.26	15,513.53
Total Debt*	0.25	1,859.00	393.17	8.18	4,720.27
Net Current Assets	-1.23	984.00	845.94	650.46	2,433.38
Contingent Liabilities	--	770.26	12.25	15.38	99.76

Cashflow (₹ Cr)

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	-0.19	-22.00	159.18	118.34	892.30
Cash Flow from Investing Activities	--	-783.00	-64.81	-223.94	-477.46
Cash from Financing Activities	0.21	409.00	-39.81	261.12	-440.83
Net Cash Inflow / Outflow	0.02	-396.00	54.56	155.52	-25.99

Ratios

Profitability Ratios

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	0.00	4.07	26.97	20.14	6.61
ROE (%)	0.00	8.38	29.77	25.18	-3.85
ROA (%)	-55.83	4.94	24.77	21.93	-2.21
EBIT Margin (%)	-17.58	15.32	20.63	34.54	1.66
Net Margin (%)	-17.58	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	--	18.37	46.65	40.90	0.78
EBIT Growth (%)	-101.18	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	-101.18	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	-101.18	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	-70.18	29.77	42.49	94.96	2.28

Valuation Ratios

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	-93.97	89.10	94.55	68.11	-89.41
Price / Book Value	13.45	7.05	20.62	15.25	3.50
Dividend Yield (%)	0.00	0.00	0.09	0.08	0.00
EV/EBITDA	-173.93	47.88	61.28	48.12	31.80
Market Cap (₹ Cr)	--	23,064.69	0.00	19,988.69	29,731.27

Solvency Ratios

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.00	0.31	0.11	0.01	0.53
Short term debt to equity ratio	-0.74	0.11	0.54	0.02	0.12
Current Ratio	0.49	1.61	2.01	3.82	1.51
Quick Ratio	0.49	1.06	1.14	2.82	0.87
Interest Coverage	--	3.13	10.09	141.16	0.53

Operating Efficiency Ratios

	Rekvina Lab	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	30.87	16.50	26.28	24.80	23.44
Asset Turnover	3.18	0.43	1.66	0.83	0.55
Receivable days	--	60.36	47.59	90.06	77.05
Inventory Days	--	64.42	62.58	61.02	77.13
Payable days	--	218.94	228.78	96.06	173.49
Cash Conversion Cycle	--	-94.15	-118.62	55.02	-19.30

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly